Tazverik (tazemetostat) for the Treatment of Epithelioid Sarcoma

Tazverik (tazemetostat) is the first FDA-approved treatment for metastatic or locally advanced epithelioid sarcoma in patients aged 16 years and older. Credit: US National Library of Medicine, National Institutes of Health, Health & Human Services.



  • Tazverik
  • Tazverik
  • Tazverik